A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib, open-label,single-arm, clinical study, aiming to investigate the safety,
tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the
Programmed Death - Ligand 1 (PD-L1) membrane receptor ) combined with capecitabine as
adjuvant chemotherapy for patients with biliary tract cancers after radical resection.After
completing 8 courses of combined treatment ,ZKAB001 was continued to be administered
separately once 3 weeks for a total of 16 cycles or 1 year.